Avenue Therapeutics Inc
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develop… Read more
Avenue Therapeutics Inc (ATXI) - Total Liabilities
Latest total liabilities as of September 2025: $1.42 Million USD
Based on the latest financial reports, Avenue Therapeutics Inc (ATXI) has total liabilities worth $1.42 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Avenue Therapeutics Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Avenue Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Avenue Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Avenue Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hypoport AG
STU:HYQ
|
Germany | €263.66 Million |
|
WACKER CHEMIE - Dusseldorf Stock Exchang
DU:WCH
|
Germany | €4.27 Billion |
|
M Vision Public Company Limited
BK:MVP
|
Thailand | ฿182.77 Million |
|
SYSCO - Dusseldorf Stock Exchang
DU:SYY
|
Germany | €23.64 Billion |
|
Glucose Health Inc
PINK:GLUC
|
USA | $535.66K |
|
ITRON (IT6.SG)
STU:IT6
|
Germany | €2.00 Billion |
|
Archidply Decor Limited
NSE:ADL
|
India | ₹245.74 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Avenue Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avenue Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avenue Therapeutics Inc (2015–2024)
The table below shows the annual total liabilities of Avenue Therapeutics Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $816.00K | -31.77% |
| 2023-12-31 | $1.20 Million | -66.58% |
| 2022-12-31 | $3.58 Million | +603.14% |
| 2021-12-31 | $509.00K | -42.55% |
| 2020-12-31 | $886.00K | -58.11% |
| 2019-12-31 | $2.12 Million | -58.98% |
| 2018-12-31 | $5.16 Million | +84.80% |
| 2017-12-31 | $2.79 Million | -66.96% |
| 2016-12-31 | $8.45 Million | +64.01% |
| 2015-12-31 | $5.15 Million | -- |